Cargando…
Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?
BACKGROUND: We determined whether the market exclusivity incentive of the European Orphan Drug Regulation results in a market monopoly or that absence of another Orphan Medicinal Product (OMP) for the same rare disorder, a so-called follow-on OMP, is a matter of time or market size. In the interest...
Autores principales: | Brabers, Anne EM, Moors, Ellen HM, van Weely, Sonja, de Vrueh, Remco LA |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185263/ https://www.ncbi.nlm.nih.gov/pubmed/21892964 http://dx.doi.org/10.1186/1750-1172-6-59 |
Ejemplares similares
-
Predictors of orphan drug approval in the European Union
por: Heemstra, Harald E., et al.
Publicado: (2008) -
Orphan drugs: Unmet societal need for non-profitable privately supplied new products
por: Moors, Ellen H.M., et al.
Publicado: (2007) -
Comparing access to orphan medicinal products in Europe
por: Zamora, Bernarda, et al.
Publicado: (2019) -
An analysis of orphan medicine expenditure in Europe: is it sustainable?
por: Mestre-Ferrandiz, Jorge, et al.
Publicado: (2019) -
Orphans in the Market: The History of Orphan Drug Policy
por: Mikami, Koichi
Publicado: (2019)